Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Multiple Myeloma 20Lymphoma, B-Cell, Marginal Zone 7Stomach Neoplasms 6Lymphoma 5Neoplasms, Plasma Cell 4Recurrence 3Dyspepsia 3Peptic Ulcer 2Gastritis 2Skin Neoplasms 1Pseudomyxoma Peritonei 1Prostatic Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lung Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, B-Cell 1Infections 1Helicobacter Infections 1Familial primary gastric lymphoma 1Chemotherapy Effect 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1Cachexia 1B-cell Malignancies 1Atrophy 1Appendiceal Neoplasms 1

Interventions

Paclitaxel 114Carboplatin 114Cisplatin 45Topotecan 43Gemcitabine 31Cyclophosphamide 31Docetaxel 28liposomal doxorubicin 27Bevacizumab 27Filgrastim 20pembrolizumab 19Peripheral Blood Stem Cell Transplantation 18Taxes 15Drug Therapy 15sargramostim 12Hyperthermic Intraperitoneal Chemotherapy 12olaparib 11Chemotherapy, Adjuvant 10Surgical Procedures, Operative 9Etoposide 9oregovomab 8mirvetuximab soravtansine 8Nivolumab 8Amifostine 8Therapeutics 7Melphalan 7Erlotinib Hydrochloride 7rucaparib 6aldesleukin 6Oxaliplatin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Carcinoma, Ovarian Epithelial × Clarithromycin × Clear all
NCT07341100 2026-06-01

Study to Evaluate the Preliminary Efficacy of SKB264 and the Effect of Clarithromycin on the PK of SKB264 in OC

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Phase 2 Active not recruiting
20 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial

Data powered by HemOnc (CC BY 4.0) Colophon âš¡